Curenetics Joins Forces with Queen Mary University London and Oracle Cancer Trust
Curenetics Joins Forces with Queen Mary University London & Oracle Cancer Trust in Revolutionary AI-Enabled Oral Cancer Test- qMIDS Supported by NIHR
Curenetics, Queen Mary University London (QMUL), Oracle Cancer Trust and South East Health Technologies Alliance (SEHTA) are working collaboratively to pioneer a transformative approach to oral cancer detection through the Novel AI-Enabled qMIDS Test. The research is funded by the National Institute for Health and Care Research (NIHR), the research partner of the NHS, public health and social care. This groundbreaking project is poised to elevate precision cancer diagnostics by harnessing the power of artificial intelligence.
The Novel AI-Enhanced qMIDS Test, an innovative fusion of state-of-the-art technologies, presents a revolutionary solution to the challenge of oral cancer diagnosis. By integrating AI with the quantitative Malignancy Index Diagnostic System (qMIDS), rapid and accurate oral cancer detection is now possible even in the presence of seemingly inconspicuous mouth lesions. The test employs reverse transcription quantitative PCR to analyze the expression levels of 16 genes (mRNA) within a minimally invasive 1-mm3 tissue biopsy. These gene expression profiles are then translated into a clinically meaningful quantitative malignancy index through an AI-powered algorithm, enabling precise stratification of cancer risk.
This cutting-edge research initiative represents a collaboration between the fields of oral cancer medicine, cancer biology and artificial intelligence. The research team is led by Dr. Sola Adeleke, Dr. Muy-Teck Teh, Dr. Barbara Carey, Gemma McKnight, and experts from SEHTA. Together they bring a wealth of expertise and a shared dedication to pushing the boundaries of cancer diagnostics.
Future Implications
Dr. Sola Adeleke, Founder of Curenetics, expressed the immense significance of this partnership: “Our collaboration with Queen Mary University London and Oracle Cancer Trust, under the auspices of NIHR, marks a giant stride in validating the Novel AI-Enhanced qMIDS Test. This research holds the potential to revolutionize the way we approach cancer diagnosis, offering an unprecedented level of accuracy and speed that has the potential to redefine patient care.”
The Novel AI-Enhanced qMIDS Test stands as a testament to the relentless pursuit of innovation in healthcare. By combining the expertise of multiple leading institutions, this research initiative underscores the commitment of all parties involved to transform the landscape of oral cancer detection and management.
As the research continues to progress, the collaborative efforts of Curenetics, Queen Mary University London, Oracle Cancer Trust, SEHTA and NIHR stand poised to redefine the future of oral cancer diagnostics, exemplifying the profound impact that can be achieved through the integration of AI and cancer medicine.
Thank you to our brilliant Great North Run runners!
This September, two incredible supporters took to the streets of Newcastle for the Great North Run, the world’s largest half marathon, and we couldn’t be prouder of them both. Beth Robinson Scales completed the 13.1-mile route in searing heat, raising over £3,800 for Oracle. Beth ran in honour of her husband Steve, following his recurrence, and…
Bringing the UK’s head and neck oncology community together
The Oracle Head & Neck Cancer UK Oncology Meeting 2026 takes place tomorrow, Friday 25th September, at The Milner Hotel, York. Now in its third year under the Oracle umbrella, this free educational meeting brings together head and neck oncology specialists from around 40 centres across the UK, spanning radiography, nursing, clinical and medical oncology,…
October Webinar: Immunotherapy & Other Developing Treatments
Professor Kevin Harrington explores the latest immunotherapy treatments for head and neck cancer in our upcoming webinar on 6 October.
Mark Hodgson walks 310km in August for Oracle Head and Neck Cancer UK
A Leeds private investigator who was treated for stage 4 cancer of the throat and tongue is walking 10 kilometres every day throughout August for Oracle Head & Neck Cancer UK. He has already passed his original £10,000 target, with 11 days of the challenge still to run. Mark Hodgson is a director of Tremark Associates, a Leeds…
September Webinar: Understanding Head & Neck cancer late effects in survivorship.
From cure to consequence:
Understanding Head & Neck cancer late effects in survivorship.
Thursday 10 September 2026
18:00 – 19:00 pm
Our Late Effects webinar will feature Sabina Khan and Emma Hallam, Macmillan Consultant Radiographers. Both specialise in head and neck post-treatment late effects. They’ll be joined by patient Karen Liesching-Schroder, who will share the patient perspective drawing on her experience of diagnosis, treatment and late effects.
Oracle launches new webinar series to support Head & Neck Cancer Patients
Oracle Head & Neck Cancer has launched its new webinar series for anyone newly diagnosed with head and neck cancer. First in the series ‘I’ve just been diagnosed. What now?” features retired Consultant Oncologist Professor Dr Mehmet Sen and patient speaker Hazel Turner. They share expert advice and personal experience to help patients and…
Newsletter June 2026
Julie Child, Executive Director It’s been a whirlwind five months since I started at Oracle Head and Neck Cancer UK. Thanks to your support and donations, the charity was successful in its Emergency Appeal and managed to secure the funds required to go forward. I’ve been very fortunate to meet a number of supporters, both…
Using the power of football to help prevent cancer
This week, Oracle Head & Neck Cancer UK has launched an important awareness campaign in partnership with Bromley FC, using the reach of football to shine a light on head and neck cancer prevention and the life-saving importance of the HPV vaccine. Throughout the week, Bromley FC is sharing trusted health information with its supporters,…
Cancer Care: Why Mental Health Support Must Be Part of Every Cancer Journey
Oracle Head & Neck Cancer UK is proud to support the Daily Express Cancer Care campaign, a powerful series that shines a light on the often unseen emotional toll of cancer – and the urgent need for better psychological support for everyone affected. The campaign published over the past three weeks featured voices from across…
Ground-breaking blood test shows promise for early detection of head & neck and other hard-to-screen cancers
A new large-scale trial has found that the blood-based screening test known as Galleri test can detect more than 50 types of cancer – including cancers of the head and neck, which currently have no routine screening programme – and may significantly boost early diagnosis. The trial showed that, when used alongside existing screening methods,…
Help Beat Head and Neck Cancer
Oracle Head & Neck Cancer UK is a registered charity in England and Wales (1142037), and in Scotland (SC052790).
Registered as a company limited by guarantee in England and Wales (7125497). Registered address: 167-169, Great Portland Street, 5th Floor, London W1W 5PF.